UniQure

About

uniQure is focused on the research and early development of human gene-based therapies.

Amsterdam,Noord-Holland,The Netherlands
101 - 250
http://www.uniqure.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $20M
Industries: Biotechnology,Genetics,Health Care,Medical
Founded date: Nov 1, 2012
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:QURE
Legal Name: uniQure N.V.

uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease.

We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$255.50M

UniQure has raised a total of $255.50M in funding over 2 rounds. Their latest funding was raised on Apr 14, 2015 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Apr 14, 2015	Post-IPO Equity	$89M	—	—	—	Detail
Jul 1, 2014	Post-IPO Debt	$20M	1	—	—	Detail
Feb 6, 2014	IPO	$88.50M	—	—	—	Detail
Jul 9, 2013	Private Equity（PE）	$58M	3	Coller Capital	—	Detail

Investors

Number of Lead Investors

Number of Investors

1

4

UniQure is funded by 4 investors. Coller Capital and Hercules Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
Coller Capital	Yes	Private Equity（PE）
Hercules Capital	—	Post-IPO Debt
Chiesi Pharmaceuticals	—	Private Equity（PE）
Forbion Capital Partners	—	Private Equity（PE）